Cord Dohrmann - Evotec AG Insider

EVOTF -- USA Stock  

USD 19.65  0.60  2.96%

Dr. Cord Dohrmann was Chief Scientific Officer and Member of the Management Board at Evotec AG since September 1, 2010. Dr. Dohrmann has spent over 20 years in biomedical research at academic institutions and in the biotech industry. He started his academic career in 1983 studying Biology at Tuebingen University in Germany and conducting research as a DAAD scholar at Duke University, Durham, USA. Dr. Dohrmann completed his MA thesis at the MaxPlanck Institute in Tuebingen and subsequently enrolled at the Harvard Medical School in Boston, USA, where he received his Ph.D. in Cell and Developmental Biology in 1996. Dr. Dohrmann continued his career as a Shiseido research fellow at the Massachusetts General Hospital in Boston before joining DeveloGen in 1999. He served the company in various management positions including CEO, leading DeveloGen from a startup to an internationally recognized metabolic disease company with a pipeline of innovative preclinical and clinical products for the treatment of diabetes and related disorders
Age: 52  Executive Since 2010      
49 40 5 60 81 0
Dohrmann was advising the European Commission, the MaxPlanckInstitute as well as VC firms and authored and coauthored a number of publications and patents. Since December 2016, Dr. Dohrmann was serving as member of the Supervisory Board of Eternygen GmbH. In June 2017, he became a member of the Supervisory Board of Facio Therapies BV.

Management Efficiency

The company has return on total asset (ROA) of 4.3 % which means that it generated profit of $4.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 6.24 % meaning that it generated $6.24 on every $100 dollars invested by stockholders.
The company has accumulated 212.96 M in total debt with debt to equity ratio (D/E) of 53.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evotec AG has Current Ratio of 0.72 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Entity Summary

Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany. Evotec AG operates under Drug Manufacturers - Specialty Generic classification in USA and traded on OTC Market. It employs 2178 people.Evotec AG (EVOTF) is traded on OTC Market in USA. It is located in Manfred Eigen Campus and employs 2,178 people.

Evotec AG Leadership Team

Werner Lanthaler, President of the Management Board, CEO
Claus Braestrup, Member of the Supervisory Board
Michael Shalmi, Member of the Supervisory Board
Mario Polywka, COO and Member of Management Board
Mary Tanner, Member of the Supervisory Board
Roland Oetker, Deputy Chairman of the Supervisory Board
Andreas Pinkwart, Member of the Supervisory Board
Paul Herrling, Member of the Supervisory Board
Colin Bond, CFO and Member of Management Board
Cord Dohrmann, Chief Scientific Officer and Member of Management Board
Iris LoewFriedrich, Member of the Supervisory Board
Bernd Hirsch, Member of the Supervisory Board
Enno Spillner, CFO, Member of the Management Board
Elaine Sullivan, Member of the Supervisory Board
Wolfgang Plischke, Chairman of the Supervisory Board

Stock Performance Indicators

Did you try this?

Run Alpha Finder Now

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Alpha Finder

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Evotec AG and Apple. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.